Literature DB >> 28860163

Proximal Tubular Cannabinoid-1 Receptor Regulates Obesity-Induced CKD.

Shiran Udi1, Liad Hinden1, Brian Earley2, Adi Drori1, Noa Reuveni1, Rivka Hadar1, Resat Cinar2, Alina Nemirovski1, Joseph Tam3.   

Abstract

Obesity-related structural and functional changes in the kidney develop early in the course of obesity and occur independently of hypertension, diabetes, and dyslipidemia. Activating the renal cannabinoid-1 receptor (CB1R) induces nephropathy, whereas CB1R blockade improves kidney function. Whether these effects are mediated via a specific cell type within the kidney remains unknown. Here, we show that specific deletion of CB1R in the renal proximal tubule cells did not protect the mice from obesity, but markedly attenuated the obesity-induced lipid accumulation in the kidney and renal dysfunction, injury, inflammation, and fibrosis. These effects associated with increased activation of liver kinase B1 and the energy sensor AMP-activated protein kinase, as well as enhanced fatty acid β-oxidation. Collectively, these findings indicate that renal proximal tubule cell CB1R contributes to the pathogenesis of obesity-induced renal lipotoxicity and nephropathy by regulating the liver kinase B1/AMP-activated protein kinase signaling pathway.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  AMPK; CB1 receptor; Endocannabinoids; Renal Proximal Tubular Cell; chronic kidney disease; obesity

Mesh:

Substances:

Year:  2017        PMID: 28860163      PMCID: PMC5698062          DOI: 10.1681/ASN.2016101085

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  68 in total

1.  Effects of cannabinoid receptors on skeletal muscle oxidative pathways.

Authors:  P Cavuoto; A J McAinch; G Hatzinikolas; D Cameron-Smith; G A Wittert
Journal:  Mol Cell Endocrinol       Date:  2006-12-21       Impact factor: 4.102

2.  AMPK mediates the initiation of kidney disease induced by a high-fat diet.

Authors:  Anne-Emilie Declèves; Anna V Mathew; Robyn Cunard; Kumar Sharma
Journal:  J Am Soc Nephrol       Date:  2011-09-15       Impact factor: 10.121

3.  Chronic administration of AM251 improves albuminuria and renal tubular structure in obese rats.

Authors:  Kayte A Jenkin; Lannie O'Keefe; Anna C Simcocks; Esther Grinfeld; Michael L Mathai; Andrew J McAinch; Deanne H Hryciw
Journal:  J Endocrinol       Date:  2015-03-24       Impact factor: 4.286

4.  Elevated cannabinoid receptor 1 and G protein-coupled receptor 55 expression in proximal tubule cells and whole kidney exposed to diabetic conditions.

Authors:  Kayte A Jenkin; Andrew J McAinch; Yuan Zhang; Darren J Kelly; Deanne H Hryciw
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-03       Impact factor: 2.557

5.  Cannabinoid receptor 1 is a major mediator of renal fibrosis.

Authors:  Lola Lecru; Christophe Desterke; Stanislas Grassin-Delyle; Christos Chatziantoniou; Sophie Vandermeersch; Aurore Devocelle; Amelia Vernochet; Ninoslav Ivanovski; Catherine Ledent; Sophie Ferlicot; Meriem Dalia; Myriam Saïd; Séverine Beaudreuil; Bernard Charpentier; Aimé Vazquez; Julien Giron-Michel; Bruno Azzarone; Antoine Durrbach; Hélène François
Journal:  Kidney Int       Date:  2015-03-11       Impact factor: 10.612

Review 6.  Association between obesity and kidney disease: a systematic review and meta-analysis.

Authors:  Y Wang; X Chen; Y Song; B Caballero; L J Cheskin
Journal:  Kidney Int       Date:  2007-10-10       Impact factor: 10.612

7.  CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.

Authors:  C Ravinet Trillou; C Delgorge; C Menet; M Arnone; P Soubrié
Journal:  Int J Obes Relat Metab Disord       Date:  2004-04

8.  The cannabinoid CB1 receptor is expressed in pancreatic delta-cells.

Authors:  William G Tharp; Yong-Ho Lee; Rhonda L Maple; Richard E Pratley
Journal:  Biochem Biophys Res Commun       Date:  2008-05-27       Impact factor: 3.575

9.  Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy.

Authors:  Federica Barutta; Serena Grimaldi; Roberto Gambino; Kiran Vemuri; Alexandros Makriyannis; Laura Annaratone; Vincenzo di Marzo; Graziella Bruno; Gabriella Gruden
Journal:  Nephrol Dial Transplant       Date:  2017-10-01       Impact factor: 5.992

10.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.

Authors:  T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

View more
  32 in total

Review 1.  Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.

Authors:  Heidi Noels; Michael Lehrke; Raymond Vanholder; Joachim Jankowski
Journal:  Nat Rev Nephrol       Date:  2021-05-10       Impact factor: 28.314

2.  Multiphoton imaging reveals axial differences in metabolic autofluorescence signals along the kidney proximal tubule.

Authors:  Milica Bugarski; Joana Raquel Martins; Dominik Haenni; Andrew M Hall
Journal:  Am J Physiol Renal Physiol       Date:  2018-08-22

3.  Novel Targets for Therapy of Renal Fibrosis.

Authors:  Niki Prakoura; Juliette Hadchouel; Christos Chatziantoniou
Journal:  J Histochem Cytochem       Date:  2019-05-22       Impact factor: 2.479

4.  Targeting Peripheral CB1 Receptors Reduces Ethanol Intake via a Gut-Brain Axis.

Authors:  Grzegorz Godlewski; Resat Cinar; Nathan J Coffey; Jie Liu; Tony Jourdan; Bani Mukhopadhyay; Lee Chedester; Ziyi Liu; Douglas Osei-Hyiaman; Malliga R Iyer; Joshua K Park; Roy G Smith; Hiroshi Iwakura; George Kunos
Journal:  Cell Metab       Date:  2019-05-16       Impact factor: 27.287

5.  Obesity-Related CKD: When Kidneys Get the Munchies.

Authors:  Peter F Mount; Luis A Juncos
Journal:  J Am Soc Nephrol       Date:  2017-10-20       Impact factor: 10.121

6.  Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy.

Authors:  Liad Hinden; Shiran Udi; Adi Drori; Asaad Gammal; Alina Nemirovski; Rivka Hadar; Saja Baraghithy; Anna Permyakova; Matan Geron; Merav Cohen; Sabina Tsytkin-Kirschenzweig; Yael Riahi; Gil Leibowitz; Yaakov Nahmias; Avi Priel; Joseph Tam
Journal:  J Am Soc Nephrol       Date:  2017-10-13       Impact factor: 10.121

7.  Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice.

Authors:  Carmelo Quarta; Daniela Cota
Journal:  Int J Obes (Lond)       Date:  2020-04-21       Impact factor: 5.095

8.  Lacking ketohexokinase-A exacerbates renal injury in streptozotocin-induced diabetic mice.

Authors:  Tomohito Doke; Takuji Ishimoto; Takahiro Hayasaki; Satsuki Ikeda; Masako Hasebe; Akiyoshi Hirayama; Tomoyoshi Soga; Noritoshi Kato; Tomoki Kosugi; Naotake Tsuboi; Miguel A Lanaspa; Richard J Johnson; Kenji Kadomatsu; Shoichi Maruyama
Journal:  Metabolism       Date:  2018-03-29       Impact factor: 8.694

9.  Circulating Endocannabinoids Are Reduced Following Bariatric Surgery and Associated with Improved Metabolic Homeostasis in Humans.

Authors:  Shahar Azar; Shiri Sherf-Dagan; Alina Nemirovski; Muriel Webb; Asnat Raziel; Andrei Keidar; David Goitein; Nasser Sakran; Oren Shibolet; Joseph Tam; Shira Zelber-Sagi
Journal:  Obes Surg       Date:  2019-01       Impact factor: 4.129

10.  Identification of novel mouse and rat CB1R isoforms and in silico modeling of human CB1R for peripheral cannabinoid therapeutics.

Authors:  Qing-Rong Liu; Nicholas S Huang; Hong Qu; Jennifer F O'Connell; Isabel Gonzalez-Mariscal; Sara Santa-Cruz-Calvo; Maire E Doyle; Zheng-Xiong Xi; Yun Wang; Emmanuel S Onaivi; Josephine M Egan
Journal:  Acta Pharmacol Sin       Date:  2018-09-10       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.